Despite the improvement in therapeutic schedules, a relevant fraction of mantle cell lymphoma (MCL) patients still experience primary treatment failure. This is due to a deep biological heterogeneity, not adequately dissected by the clinical predictors alone, as the MIPI (MCL International Prognostic Index). The Fondazione Italiana Linfomi (FIL) MCL0208 trial (NCT02354313) is a prospective, randomized phase III trial comparing lenalidomide maintenance vs observation after an intensive citarabine containing chemo-immunotherapy followed by autologous transplantation in frontline MCL patients <66 years.[Ladetto, ASH 2018] Several biological ancillary studies were planned upfront, prospectively investigating the prognostic impact of putative biomarkers. Here we present a comprehensive analysis of the clinical impact of all the identified biopredictors.

COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL

Ferrero, S.;Zaccaria, G. M.;Barbero, D.;Evangelista, A.;Cavallo, F.;Ghislieri, M.;Omedè, P.;Zamò, A.;Ciccone, G.;GAIDANO, Giampiero;Ladetto, M.
2019-01-01

Abstract

Despite the improvement in therapeutic schedules, a relevant fraction of mantle cell lymphoma (MCL) patients still experience primary treatment failure. This is due to a deep biological heterogeneity, not adequately dissected by the clinical predictors alone, as the MIPI (MCL International Prognostic Index). The Fondazione Italiana Linfomi (FIL) MCL0208 trial (NCT02354313) is a prospective, randomized phase III trial comparing lenalidomide maintenance vs observation after an intensive citarabine containing chemo-immunotherapy followed by autologous transplantation in frontline MCL patients <66 years.[Ladetto, ASH 2018] Several biological ancillary studies were planned upfront, prospectively investigating the prognostic impact of putative biomarkers. Here we present a comprehensive analysis of the clinical impact of all the identified biopredictors.
European Hematology Association (EHA)
Amsterdam
13/06/2019 - 16/06/2019
HemaSphere
3
569
570
https://journals.lww.com/hemasphere/Fulltext/2019/06001/COMPREHENSIVE_ANALYSIS_OF_BASELINE_OUTCOME.1134.aspx
Ferrero, S.; Zaccaria, G. M.; Barbero, D.; Evangelista, A.; Di Rocco, A.; Re, A.; Stefoni, V.; Cavallo, F.; Vitolo, U.; Balzarotti, M.; Rusconi, C.; da Silva, Gomes M.; Ghislieri, M.; Omedè, P.; Zamò, A.; Ciccone, G.; Gattei, V.; Gaidano, G.; Cortelazzo, S.; Ladetto, M.
File in questo prodotto:
File Dimensione Formato  
COMPREHENSIVE_ANALYSIS_OF_BASELINE_OUTCOME.1134.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 602.72 kB
Formato Adobe PDF
602.72 kB Adobe PDF Visualizza/Apri
EHA_2019_Ferrero.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 2.7 MB
Formato Adobe PDF
2.7 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1714232
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact